AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12047485
Drug: Ketamine (0.375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.375 mg kg(‐1))
Trial: 10091823
Drug: Amiodarone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (300 mg intravenously over 1 h, followed by 20 mg/kg over the next 24 h plus 600 mg orally, in three doses, for 1 week, then 400 mg/day orally, for three weeks)
Trial: 10091823
Drug: Propafenone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (2 mg/kg intravenously over 15 min, followed by 10 mg/kg over 24 h and then 450 mg/day orally, for one month)
Trial: 8543508
Drug: Therapy for
RxNorm normalized name: nutritional therapy for GSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy for sexually abused children
Trial: 8543508
Drug: Future sexual
RxNorm normalized name: Zinc Gluconate 50 mg ORAL CAPSULE [Pegasus Male Sexual Enhancer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Future sexual abuse therapy outcome research considerations
Trial: 2407764
Drug: Ornithine alpha-ketoglutarate
RxNorm normalized name: ornithine alpha-ketoglutarate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ornithine alpha-ketoglutarate (OKG) 10 g (3.6 g alpha KG and 6.4 g ORN)
Trial: 2407764
Drug: Ornithine hydrochloride
RxNorm normalized name: Ornithine hydrochloride
DrugBank: Ornithine (DB00129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ornithine hydrochloride 6.4 g
Trial: 2407764
Drug: Calcium alpha-ketoglutarate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium alpha-ketoglutarate 3.6 g
Trial: 373415
Drug: L-Histidine, 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Histidine, 4 g/day
Trial: 7109499
Drug: VAC/FMC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAC/FMC plus 5 mg/m2 Corynebacterium parvum (CP) subcutaneously on day 1
Trial: 30917820
Drug: Group (G)
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group (G)
Trial: 21822934
Drug: Intravenous 10%
RxNorm normalized name: fat emulsion, intravenous 10% intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 10% caprylate-chromatography purified immunoglobulin
Trial: 19348602
Drug: Bromfenac sodium
RxNorm normalized name: Bromfenac Sodium
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bromfenac sodium (BF) 0.1% ophthalmic solution with disodium cromoglycate (DSCG) 2.0%
Trial: 19348602
Drug: Fluorometholone (FML)
RxNorm normalized name: Fluorometholone
DrugBank: Fluorometholone (DB00324)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluorometholone (FML) 0.02% ophthalmic suspension with disodium cromoglycate (DSCG) 2.0%
Trial: 19348602
Drug: Patient preference
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient preference for concomitant treatment
Trial: 17472472
Drug: Seaweed (Alaria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seaweed (Alaria esculenta), 5 g/day for 7 weeks
Trial: 17472472
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein isolate, 141.3 mg of isoflavones/day for the last week of each treatment arm
Trial: 17472472
Drug: Placebo, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 5 g/day for 7 weeks
Trial: 11981081
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (6 g/day)
Trial: 7726397
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 6 mg.kg‐1.h‐1
Trial: 7726397
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 12 mg.kg‐1.h‐1
Trial: 2074175
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for restoration of venous patency and valvular function
Trial: 2074175
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment with heparin, oral anticoagulants, and compression stockings
Trial: 2074175
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for ilio-femoral DVT
Trial: 2074175
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment for ilio-femoral DVT
Trial: 20842109
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg, vitamin C 1 g, and vitamin E 1,000 IU
Trial: 15565596
Drug: Surgery plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery plus preoperative treatment with recombinant human IL‐2 (34 patients)
Trial: 12445025
Drug: rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 10 mg orally each morning (07.00 h)
Trial: 12445025
Drug: rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 10 mg orally each evening (18.00 h)
Trial: 10662482
Drug: Coformulation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coformulation of low dose aspirin plus modified-release dipyridamole
Trial: 2304776
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A treatment for 4 months
Trial: 2304776
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A treatment
Trial: 6775296
Drug: isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: isosorbide dinitrate (ID) 5 mg
Trial: 6775296
Drug: nitroglycerin microcapsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nitroglycerin microcapsules (NGMC) 7.5 mg
Trial: 6775296
Drug: pentaerythritol tetranitrate
RxNorm normalized name: Pentaerythritol tetranitrate
DrugBank: Pentaerythritol tetranitrate (DB06154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pentaerythritol tetranitrate (PETN) 160 mg
Trial: 30496299
Drug: HIV‐DNA intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV‐DNA intradermal priming regimens (Group I: 2x0.1mL [3mg/mL], Group II: 2x0.1mL [3mg/mL] plus electroporation, Group III: 1x0.1mL [6mg/mL] plus electroporation)
Trial: 30496299
Drug: HIV‐MVA administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV‐MVA administered with or without CN54rgp140/GLA‐AF
Trial: 26399404
Drug: Bedtime ingestion
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime ingestion of hypertension medications
Trial: 26399404
Drug: Morning ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning ingestion of hypertension medications
Trial: 24788781
Drug: Monthly household
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly household food basket (FB) plus nutrition education (NE)
Trial: 30509271
Drug: Metformin (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (2000 mg daily)
Trial: 20196651
Drug: History of
RxNorm normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: History of TB treatment
Trial: 19137863
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia (tetracaine 0.5% eye drops and preservative free lidocaine 2% intracamerally)
Trial: 19137863
Drug: Retrobulbar anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrobulbar anesthesia (4 mL lidocaine 2% into the retrobulbar space)
Trial: 15771597
Drug: Prostaglandin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin therapy
Trial: 10760336
Drug: Customary diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Customary diet with placebo pill for 2 menstrual cycles
Trial: 8558188
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate 800 mg/d orally
Trial: 27638452
Drug: Telemedicine intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telemedicine intervention (not specified dosage or duration)
Trial: 24841866
Drug: Family Behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family Behavior Therapy (FBT)
Trial: 17617527
Drug: Weekly intravenous
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly intravenous cisplatin at 40 mg/m2 for 6 weeks in combination with radiation therapy (RT)
Trial: 16228060
Drug: Ketoconazole (KCZ)
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole (KCZ) administered during the stimulation phase to 28 patients.
Trial: 24511648
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with baseline eGFR < 60 ml/min (Intervention vs Control)
Trial: 24511648
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with baseline eGFR >= 60 ml/min (Intervention vs Control)
Trial: 21700760
Drug: Multimodal nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal nutritional rehabilitation (health education, oral nutritional supplements, exercise, oral testosterone) for 90 days
Trial: 18347680
Drug: Quercetin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin (1000 mg daily for 6 weeks)
Trial: 18347680
Drug: Placebo (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1000 mg daily for 6 weeks)
Trial: 14653888
Drug: Cetrorelix (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetrorelix (3 mg single dose)
Trial: 3174724
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g fructose-1,6-diphosphate (FDP)
Trial: 6122939
Drug: 7.5 g
RxNorm normalized name: glucose 15 GM per 37.5 GM Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 g dextrose
Trial: 29904824
Drug: Monthly minodronate
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly minodronate 50 mg every 4 weeks
Trial: 29904824
Drug: Weekly alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly alendronate or risedronate
Trial: 26779704
Drug: Training program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training program 'Active and safe with wheeled walkers' for 10 weeks (90 min, twice a week)
Trial: 1105502
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg of salmefamol given by metered aerosol
Trial: 8153718
Drug: Subcutaneous adrenaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous adrenaline
Trial: 1105502
Drug: Subcutaneous atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous atropine
Trial: 31826336
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (540,000 IU single enteral dose)
Trial: 27790824
Drug: G‐CSF combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF combined with intramyocardial (i.m.) injection of autologous bone marrow-derived cells (BMCs)
Trial: 27790824
Drug: G‐CSF with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF with intracoronary (i.c.) injection of BMCs or serum (placebo)
Trial: 27790824
Drug: G‐CSF with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF with peripheral placebo (saline only)
Trial: 21829466
Drug: 30 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 µg GMZ2
Trial: 21829466
Drug: 100 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 µg GMZ2
Trial: 21829466
Drug: GMZ2 (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMZ2 (both doses)
Trial: 11339782
Drug: Diclofenac 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 100 mg suppository
Trial: 7919313
Drug: Control (non-steroid)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (non-steroid)
Trial: 3210286
Drug: Bland meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bland meal with 1950 mg of aspirin (positive control)
Trial: 3210286
Drug: Spicy Mexican
RxNorm normalized name: Mexican tea pollen extract
DrugBank: Chenopodium ambrosioides pollen (DB10479)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spicy Mexican meal (30 g of jalapeño peppers)
Trial: 868133
Drug: Isoniazid preventive
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid preventive treatment (300 mg daily for 24 weeks)
Trial: 26382173
Drug: PTAS plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTAS plus aggressive medical therapy
Trial: 22367664
Drug: Methylphenidate delivered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate delivered through a long‐acting transdermal system (MTS) for 3 months
Trial: 22367664
Drug: No-medication condition
RxNorm normalized name: salicylic acid Medicated Liquid Soap [No Zit Sherlock]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-medication condition for 3 months
Trial: 19697299
Drug: Reminiscence therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reminiscence therapy (8 sessions over 2 months)
Trial: 19697299
Drug: Comparison group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison group (no reminiscence therapy)
Trial: 8106694
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy (recombinant tissue‐type plasminogen activator, urokinase or combination therapy) with heparin, aspirin, and calcium‐channel blocking agent.
Trial: 2520637
Drug: Histamine-receptor blockade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine-receptor blockade with 10 mg of chlorpheniramine and 400 mg of cimetidine intravenously before protamine infusion.
Trial: 2520637
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no histamine-receptor blockade).
Trial: 19381522
Drug: Inhaled milrinone
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled milrinone administered via jet nebulizer for 4 hours
Trial: 19381522
Drug: Intravenous milrinone
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous milrinone (50 microg/kg bolus, then 0.5 microg/kg/min infusion for 4 hours)
Trial: 10912546
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) therapy, 4 IU/m2 per day, for a maximum of 8 years
Trial: 3555046
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin (750 mg twice daily)
Trial: 3555046
Drug: Other antimicrobial
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antimicrobial therapy
Trial: 29749371
Drug: Modafinil (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (100 mg twice a day)
Trial: 29749371
Drug: Intranasal mometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal mometasone furoate (100 µg in the evening)
Trial: 27549387
Drug: Propofol-remifentanil anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol-remifentanil anesthesia with rocuronium 0.3 mg/kg
Trial: 27549387
Drug: Propofol-remifentanil anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol-remifentanil anesthesia with rocuronium 0.6 mg/kg
Trial: 27549387
Drug: Propofol-remifentanil anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol-remifentanil anesthesia with rocuronium 0.9 mg/kg
Trial: 27549387
Drug: Sevoflurane-remifentanil anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevoflurane-remifentanil anesthesia with rocuronium 0.3 mg/kg
Trial: 27549387
Drug: Sevoflurane-remifentanil anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevoflurane-remifentanil anesthesia with rocuronium 0.6 mg/kg
Trial: 27549387
Drug: Sevoflurane-remifentanil anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevoflurane-remifentanil anesthesia with rocuronium 0.9 mg/kg
Trial: 17920718
Drug: Interferon-alpha treatment
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha treatment for 52 weeks
Trial: 16110408
Drug: Molecular targeted
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecular targeted therapy (tyrosine kinase inhibitors, anti-sense oligonucleotides, angiogenesis inhibitors, endothelin receptor antagonists)
Trial: 12409680
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitors (SSRIs) (n=743)
Trial: 10567778
Drug: gemifloxacin, 320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemifloxacin, 320 mg p.o. once daily
Trial: 44375
Drug: Sulpiride (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (400 ‐‐ 2100 mg/day)
Trial: 28741675
Drug: Dinalbuphine sebacate
RxNorm normalized name: Dinalbuphine sebacate
DrugBank: Dinalbuphine sebacate (DB15341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinalbuphine sebacate (DNS) 150 mg
Trial: 28741675
Drug: Nalbuphine HCl
RxNorm normalized name: nalbuphine HCl
DrugBank: Nalbuphine (DB00844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nalbuphine HCl 20 mg
Trial: 23721547
Drug: Arbaclofen placarbil
RxNorm normalized name: Arbaclofen Placarbil
DrugBank: Arbaclofen Placarbil (DB08892)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arbaclofen placarbil (20 or 40 mg once daily, 20 or 30 mg twice daily)
Trial: 23721547
Drug: Arbaclofen placarbil
RxNorm normalized name: Arbaclofen Placarbil
DrugBank: Arbaclofen Placarbil (DB08892)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arbaclofen placarbil (all doses)
Trial: 19654232
Drug: Dialysate calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate calcium concentration (D(Ca)) of 1.00 mmol/L
Trial: 19654232
Drug: Dialysate calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate calcium concentration (D(Ca)) of 1.50 mmol/L
Trial: 19654232
Drug: Dialysate calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate calcium concentration (D(Ca)) of 1.25 mmol/L
Trial: 15677600
Drug: Buprenorphine (12-16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (12-16 mg)
Trial: 15677600
Drug: Methadone (65-85
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (65-85 mg p.o.)
Trial: 10592952
Drug: Syrup of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syrup of ipecac (SI) + home observation (HO)
Trial: 8725983
Drug: Antibiotics for
RxNorm normalized name: ANTIBIOTICS FOR TOPICAL USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics for respiratory tract infections
Trial: 27770561
Drug: elbasvir (EBR)
DrugBank: Elbasvir (DB11574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: elbasvir (EBR) 50 mg/grazoprevir (GZR) 100 mg with sofosbuvir (SOF) 400 mg for 4 weeks
Trial: 27770561
Drug: elbasvir (EBR)
DrugBank: Elbasvir (DB11574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: elbasvir (EBR) 50 mg/grazoprevir (GZR) 100 mg with sofosbuvir (SOF) 400 mg for 6 weeks
Trial: 27770561
Drug: elbasvir (EBR)
DrugBank: Elbasvir (DB11574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: elbasvir (EBR) 50 mg/grazoprevir (GZR) 100 mg with sofosbuvir (SOF) 400 mg for 8 weeks
Trial: 27770561
Drug: elbasvir (EBR)
DrugBank: Elbasvir (DB11574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: elbasvir (EBR) 50 mg/grazoprevir (GZR) 100 mg with sofosbuvir (SOF) 400 mg for 12 weeks
Trial: 27376706
Drug: Sofosbuvir 400
RxNorm normalized name: sofosbuvir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir 400 mg once daily plus ribavirin 1,000 mg/day for 16 weeks
Trial: 27376706
Drug: Sofosbuvir 400
RxNorm normalized name: sofosbuvir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir 400 mg once daily plus ribavirin 1,000 mg/day for 24 weeks
Trial: 27376706
Drug: Sofosbuvir 400
RxNorm normalized name: sofosbuvir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir 400 mg once daily plus ribavirin 1,200 mg/day for 16 weeks
Trial: 27376706
Drug: Sofosbuvir 400
RxNorm normalized name: sofosbuvir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir 400 mg once daily plus ribavirin 1,200 mg/day for 24 weeks
Trial: 22364892
Drug: onabotulinumtoxinA (botulinum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: onabotulinumtoxinA (botulinum toxin injection to the glabellar region)